Sign in Subscribe
Class action lawsuits

Securities Lawsuit Filed Against Centene Corporation and Senior Executives

Strategic Insights

— 1 min read

A lawsuit has been filed against Centene Corporation, a leading healthcare company, and certain of its senior executives for potential violations of the federal securities laws. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Centene securities. The case is pending in the U.S. District Court for the Southern District of New York.

Centene, which provides services to consumers enrolled in government-sponsored healthcare programs like Medicaid and Medicare, had announced financial guidance for fiscal year 2025, citing stability in earnings power despite "unprecedented headwinds." However, an independent actuarial report revealed lower-than-expected enrollment growth and higher-than-anticipated morbidity rates in the markets Centene serves. The stock price fell by over 40% following the report's release.

Key Takeaways:

  • Centene, a healthcare company, has been sued for potential securities law violations by a leading securities law firm, Bleichmar Fonti & Auld LLP.
  • The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Centene securities.
  • Centene's stock price fell by over 40% after the company withdrew its guidance following an independent actuarial report revealing lower-than-expected enrollment growth and higher-than-anticipated morbidity rates in the markets it serves.
  • The complaint alleges that the majority of the market that Centene serves was experiencing lower-than-expected enrollment growth and increased morbidity rates.
  • The case is pending in the U.S. District Court for the Southern District of New York.
  • Investors who purchased Centene securities may have legal options and are encouraged to submit their information to the firm.

Statistics:

  • The stock price of Centene fell by $22.87 per share, or 40%, after the company withdrew its guidance.
  • The price of Centene stock fell from $56.65 per share on July 1, 2025, to $33.78 per share on July 2, 2025.
  • The company's stock price decline exceeded 40% in a single day.

Sources:

  • GlobeNewswire, Aug. 21, 2025
  • Centene Corporation, Dec. 12, 2024 press release
  • Centene Corporation, Feb. 4, 2025 press release
  • Centene Corporation, Apr. 25, 2025 press release
  • Wakely Consulting Group, actuarial report to Centene
  • Bleichmar Fonti & Auld LLP, firm website
  • Chambers USA
  • The Legal 500
  • ISS SCAS
  • National Law Journal
  • Lawdragon
  • Law360
  • Thomson Reuters

Read more